Advanced Accelerator Applications

Advanced Accelerator Applications (AAA) is a pharmaceutical group specialized in the field of nuclear medicine. 
The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.
In late October 2017, "Reuters" announced that Novartis would acquire the company for $3.9 billion, paying $41 per ordinary share and $82 per American depositary share representing a 47 percent premium. On January 22, 2018, Novartis AG (NYSE: NVS) announced the successful completion of the tender offer by its subsidiary, Novartis Groupe France S.A.
History.
AAA was created in 2002 by Italian physicist Stefano Buono to exploit a patent from the European Organization for Nuclear Research (CERN). 
AAA currently has a total of 31 sites in 12 countries, including: 19 production facilities in 8 countries (in Europe and the U.S.) that manufacture targeted radioligand therapies and precision imaging radioligands, and 6 sites with R&D activity.
Products.
AAA has a portfolio of diagnostic and therapeutic applications and products in the fields of Molecular Imaging and Therapy. 
The group’s portfolio of radiopharmaceuticals includes radioactive agents for positron emission tomography (PET) imaging as well as single-photon emission computed tomography (SPECT) diagnostic products.
Lutathera.
The company's lead product is LUTATHERA, a Lutetium Lu 177 dotatate 
External links.
[[Category:Pharmaceutical companies of France]]
[[Category:French companies established in 2002]]
[[Category:Pharmaceutical companies established in 2002]]
[[Category:Companies based in Auvergne-Rhône-Alpes]]